Ae1 Ae3 Antibody Bafilomycin A1 Bile Acid Assay Bioassay Blog Choline Acetyltransferase Antibody Deoxycholic Acid Sodium Salt ELISA kit Epz 6438 exosome F Actin Antibody Glycodeoxycholic Acid Hdac Activity Assay Ldn 193189 Medium Mip 1B Mothers Against Decapentaplegic Pamabrom 100Mg Pepstatin A peptide Phospho 4Ebp1 Polyclonal Soft Agar Sr 9011 Trypsin Activity Assay
Identification of Potential Kinase Inhibitors within the PI3K/AKT Pathway of Leishmania Species
Leishmaniasis is a public well being illness that requires the event of more practical remedies and the identification of novel molecular targets. Since blocking the PI3K/AKT pathway has been efficiently studied as an efficient anticancer technique for many years, we examined whether or not the identical method would even be possible in Leishmania on account of their excessive quantity and numerous set of annotated proteins.
Right here, we used a finest reciprocal hits protocol to establish potential protein kinase homologues in an annotated human PI3K/AKT pathway. We calculated their ligandibility primarily based on accessible bioactivity knowledge of the reported homologues and modelled their 3D buildings to estimate the druggability of their binding pockets.
The fashions have been used to run a digital screening methodology with molecular docking. We discovered and studied 5 protein kinases in 5 completely different Leishmania species, that are AKT, CDK, AMPK, mTOR and GSK3 homologues from the studied pathways.
The compounds discovered for various enzymes an
d species have been analysed and advised as start line scaffolds for the design of inhibitors. We studied the kinases’ participation in protein-protein interplay networks, and the potential deleterious results, if inhibited, have been supported with the literature.
Within the case of Leishmania GSK3, an inhibitor of its human counterpart, prioritized by our methodology, was validated in vitro to check its anti-Leishmania exercise and not directly infer the presence of the enzyme within the parasite. The evaluation contributes to bettering the information concerning the presence of comparable signalling pathways in Leishmania, in addition to the invention of compounds appearing towards any of those kinases as potential molecular targets within the parasite.
Endolysosomal Cation Channels and MITF in Melanocytes and Melanoma
Microphthalmia-associated transcription issue (MITF) is the principal transcription issue regulating pivotal processes in melanoma cell improvement, development, survival, proliferation, differentiation and invasion. In recent times, convincing proof has been offered testifying key roles of endolysosomal cation channels, particularly TPCs and TRPMLs, in most cancers, together with breast most cancers, glioblastoma, bladder most cancers, hepatocellular carcinoma and melanoma.
On this evaluate, we offer a gene expression profile of those channels in several types of cancers and decipher their roles, particularly the roles of two-pore channel 2 (TPC2) and TRPML1 in melanocytes and melanoma. We particularly focus on the signaling cascades regulating MITF and the connection between endolysosomal cation channels, MAPK, canonical Wnt/GSK3 pathways and MITF.
Lithium as a Neuroprotective Agent for Bipolar Dysfunction: An Overview
Lithium (Li+) is a primary possibility therapy for grownup acute episodes of Bipolar Dysfunction (BD) and for the prophylaxis of recent depressed or manic episodes. Additionally it is the popular selection as upkeep therapy. Quite a few research have proven morphological abnormalities within the brains of BD sufferers, suggesting that this extremely heritable dysfunction might exhibit progressive and deleterious adjustments in mind construction.
Since therapy with Li+ ameliorates these abnormalities, it has been postulated that Li+ is a neuroprotective agent in the identical manner atypical antipsychotics are neuroprotective in sufferers identified with schizophrenia spectrum issues. Li+‘s neuroprotective properties are associated to its modulation of nerve development elements, irritation, mitochondrial operate, oxidative stress, and programmed cell dying mechanisms akin to autophagy and apoptosis.
However, it isn’t identified whether or not Li+-induced neuroprotection is said to the inhibition of its putative molecular targets in a BD episode: the enzymes inositol-monophosphatase, (IMPase), glycogen-synthase-kinase 3β (GSK3), and Protein kinase C (PKC).
Moreover, it’s unsure whether or not these neuroprotective mechanisms are correlated with Li+‘s medical efficacy in sustaining temper stability. It’s anticipated that in a close-by future, precision medication approaches will enhance analysis and broaden therapy choices. This can actually contribute to ameliorating the medical and financial burden created by this devastating temper dysfunction.
Stemness-Suppressive Impact of Bibenzyl from Dendrobium ellipsophyllum in Human Lung Most cancers Stem-Like Cells
Most cancers stem-like cells (CSCs) are key mediators driving tumor initiation, metastasis, therapeutic failure, and subsequent most cancers relapse. Thus, focusing on CSCs has not too long ago emerged as a possible technique to enhance chemotherapy. On this examine, the anticancer exercise and stemness-regulating capability of 4,5,4′-trihydroxy-3,3′-dimethoxybibenzyl (TDB), a bibenzyl extracted from Dendrobium ellipsophyllum, are revealed in CSCs of varied human lung most cancers cells.
Tradition with TDB (5-10 μM) strongly abolished tumor-initiating cells in lung most cancers H460, H23, and A549 cells in each anchorage-dependent and anchorage-independent colony formation assays. Via the 3D single-spheroid formation mannequin, attenuation of self-renewal capability was noticed in CSC-enriched populations handled with 1-10 μM TDB for 7 days.
Stream cytometry evaluation confirmed the attenuation of %cell overexpressing CD133, a CSC biomarker, in TDB-treated lung most cancers spheroids. TDB at 5-10 μM remarkably suppressed regulatory indicators of p-Akt/Akt, p-GSK3β/GSK3β, and β-catenin similar to the downregulated mRNA degree of stemness transcription elements together with Nanog, Oct4, and Sox2. Furthermore, the antiapoptosis Bcl-2 and Mcl-1 proteins, that are downstream molecules of Akt signaling, have been evidently decreased in CSC-enriched spheroids after tradition with TDB (1-10 μM) for 24 h.
Apparently, the diminution of Akt expression by particular siAkt successfully reversed suppressive exercise of TDB focusing on on the CSC phenotype in human lung most cancers cells. These findings present promising proof of the inhibitory impact of TDB towards lung CSCs through suppression of Akt/GSK3β/β-catenin cascade and associated proteins, which might facilitate the event of this bibenzyl pure compound as a novel CSC-targeted therapeutic method for lung most cancers therapy.
Temper Regulatory Actions of Energetic and Sham Nucleus Accumbens Deep Mind Stimulation in Antidepressant Resistant Rats
The antidepressant actions of deep mind stimulation (DBS) are related to progressive neuroadaptations throughout the temper community, modulated partly, by neurotrophic mechanisms. We investigated the antidepressant-like results of continual nucleus accumbens (NAc) DBS and its affiliation with change in glycogen synthase kinase 3 (GSK3) and mammalian goal of rapamycin (mTOR) expression within the infralimbic cortex (IL), and the dorsal (dHIP) and ventral (vHIP) subregions of the hippocampus of antidepressant resistant rats.
Antidepressant resistance was induced through each day injection of adrenocorticotropic hormone (ACTH; 100 μg/day; 15 days) and confirmed by non-response to tricyclic antidepressant therapy (imipramine, 10 mg/kg). Moveable microdevices offered steady bilateral NAc DBS (130 Hz, 200 μA, 90 μs) for 7 days. A management sham electrode group was included, along with ACTH- and saline-treated management teams.
Dwelling cage monitoring, open subject, sucrose desire, and, pressured swim behavioral checks have been carried out. Submit-mortem ranges of GSK3 and mTOR, complete and phosphorylated, have been decided with Western blot.
As beforehand reported, ACTH therapy blocked the immobility-reducing results of imipramine within the pressured swim check. In distinction, therapy with both energetic DBS or sham electrode placement within the NAc considerably lowered pressured swim immobility time in ACTH-treated animals.
This was related to elevated homecage exercise within the DBS and sham teams relative to ACTH and saline teams, nonetheless, no variations in locomotor exercise have been noticed within the open subject check, nor have been any group variations seen for sucrose consumption throughout teams.
GSK744 (S/GSK1265744) |
|||
| A8566-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 236.4 |
|
Description: GSK744 (S/GSK1265744) is a potential inhibitor of HIV integrase with IC50 value of 3 nM [1].HIV integrase is an enzyme produced by HIV virus that enables its genetic material to be integrated into the infected cell DNA. |
|||
GSK744 (S/GSK1265744) |
|||
| A8566-50 | ApexBio | 50 mg | EUR 895.2 |
|
Description: GSK744 (S/GSK1265744) is a potential inhibitor of HIV integrase with IC50 value of 3 nM [1].HIV integrase is an enzyme produced by HIV virus that enables its genetic material to be integrated into the infected cell DNA. |
|||
Gsk1120212 |
|||
| 20-abx182481 | Abbexa |
|
|
GSK-1070916 |
|||
| B1939-25 | Biovision | each | EUR 907.2 |
GSK-1070916 |
|||
| B1939-5 | Biovision | each | EUR 274.8 |
GSK-2018682 |
|||
| B1967-25 | Biovision | each | EUR 757.2 |
GSK-2018682 |
|||
| B1967-5 | Biovision | each | EUR 235.2 |
GSK2334470 |
|||
| B2174-10 | ApexBio | 10 mg | EUR 205.2 |
|
Description: GSK2334470 is a highly specific inhibitor of 3-phosphoinositide-dependent protein kinase 1(PDK1) with IC50 value of ~10nM [1].GSK2334470 prevents PDK1 from activating full-length Akt1or mutant Akt1 lacking the PH domain. |
|||
GSK2334470 |
|||
| B2174-25 | ApexBio | 25 mg | EUR 351.6 |
|
Description: GSK2334470 is a highly specific inhibitor of 3-phosphoinositide-dependent protein kinase 1(PDK1) with IC50 value of ~10nM [1].GSK2334470 prevents PDK1 from activating full-length Akt1or mutant Akt1 lacking the PH domain. |
|||
GSK2334470 |
|||
| B2174-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 240 |
|
Description: GSK2334470 is a highly specific inhibitor of 3-phosphoinositide-dependent protein kinase 1(PDK1) with IC50 value of ~10nM [1].GSK2334470 prevents PDK1 from activating full-length Akt1or mutant Akt1 lacking the PH domain. |
|||
GSK2334470 |
|||
| B2174-50 | ApexBio | 50 mg | EUR 517.2 |
|
Description: GSK2334470 is a highly specific inhibitor of 3-phosphoinositide-dependent protein kinase 1(PDK1) with IC50 value of ~10nM [1].GSK2334470 prevents PDK1 from activating full-length Akt1or mutant Akt1 lacking the PH domain. |
|||
GSK2656157 |
|||
| B2175-10 | ApexBio | 10 mg | EUR 226.8 |
|
Description: GSK2656157 is a highly selective inhibitor of protein kinase R-like ER kinase (PERK) with IC50 value of 0.9nM [1].GSK2656157 is highly selective for PERK enzyme against a panel of 300 kinases. |
|||
GSK2656157 |
|||
| B2175-100 | ApexBio | 100 mg | EUR 706.8 |
|
Description: GSK2656157 is a highly selective inhibitor of protein kinase R-like ER kinase (PERK) with IC50 value of 0.9nM [1].GSK2656157 is highly selective for PERK enzyme against a panel of 300 kinases. |
|||
GSK2656157 |
|||
| B2175-5 | ApexBio | 5 mg | EUR 184.8 |
|
Description: GSK2656157 is a highly selective inhibitor of protein kinase R-like ER kinase (PERK) with IC50 value of 0.9nM [1].GSK2656157 is highly selective for PERK enzyme against a panel of 300 kinases. |
|||
GSK2656157 |
|||
| B2175-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 196.8 |
|
Description: GSK2656157 is a highly selective inhibitor of protein kinase R-like ER kinase (PERK) with IC50 value of 0.9nM [1].GSK2656157 is highly selective for PERK enzyme against a panel of 300 kinases. |
|||
GSK2656157 |
|||
| B2175-50 | ApexBio | 50 mg | EUR 414 |
|
Description: GSK2656157 is a highly selective inhibitor of protein kinase R-like ER kinase (PERK) with IC50 value of 0.9nM [1].GSK2656157 is highly selective for PERK enzyme against a panel of 300 kinases. |
|||
GSK1059615 |
|||
| B2176-10 | ApexBio | 10 mg | EUR 219.6 |
|
Description: GSK1059615 is inhibitor of pan-PI3K with IC50 values of 0.4nM, 0.6nM, 5nM, 2nM and 12nM for PI3K?, P13K?, P13K?, P13K? and mTOR, respectively [1].GSK1059615 is a potent and reversible inhibitor of P13K. |
|||
GSK1059615 |
|||
| B2176-25 | ApexBio | 25 mg | EUR 435.6 |
|
Description: GSK1059615 is inhibitor of pan-PI3K with IC50 values of 0.4nM, 0.6nM, 5nM, 2nM and 12nM for PI3K?, P13K?, P13K?, P13K? and mTOR, respectively [1].GSK1059615 is a potent and reversible inhibitor of P13K. |
|||
GSK1059615 |
|||
| B2176-5 | ApexBio | 5 mg | EUR 170.4 |
|
Description: GSK1059615 is inhibitor of pan-PI3K with IC50 values of 0.4nM, 0.6nM, 5nM, 2nM and 12nM for PI3K?, P13K?, P13K?, P13K? and mTOR, respectively [1].GSK1059615 is a potent and reversible inhibitor of P13K. |
|||
GSK1059615 |
|||
| B2176-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 266.4 |
|
Description: GSK1059615 is inhibitor of pan-PI3K with IC50 values of 0.4nM, 0.6nM, 5nM, 2nM and 12nM for PI3K?, P13K?, P13K?, P13K? and mTOR, respectively [1].GSK1059615 is a potent and reversible inhibitor of P13K. |
|||
GSK1059615 |
|||
| B2176-50 | ApexBio | 50 mg | EUR 748.8 |
|
Description: GSK1059615 is inhibitor of pan-PI3K with IC50 values of 0.4nM, 0.6nM, 5nM, 2nM and 12nM for PI3K?, P13K?, P13K?, P13K? and mTOR, respectively [1].GSK1059615 is a potent and reversible inhibitor of P13K. |
|||
GSK2636771 |
|||
| B2186-10 | ApexBio | 10 mg | EUR 258 |
|
Description: GSK2636771 is a p110? isoform-specific inhibitor of PIK3 with SF50 more than 1 ?M [1].PI3K (phosphatidylinositol 3-kinase) has 4 catalytic subunits: p110?, ?, ?, ??and ?. |
|||
GSK2636771 |
|||
| B2186-100 | ApexBio | 100 mg | EUR 787.2 |
|
Description: GSK2636771 is a p110? isoform-specific inhibitor of PIK3 with SF50 more than 1 ?M [1].PI3K (phosphatidylinositol 3-kinase) has 4 catalytic subunits: p110?, ?, ?, ??and ?. |
|||
GSK2636771 |
|||
| B2186-5 | ApexBio | 5 mg | EUR 165.6 |
|
Description: GSK2636771 is a p110? isoform-specific inhibitor of PIK3 with SF50 more than 1 ?M [1].PI3K (phosphatidylinositol 3-kinase) has 4 catalytic subunits: p110?, ?, ?, ??and ?. |
|||
GSK2636771 |
|||
| B2186-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 184.8 |
|
Description: GSK2636771 is a p110? isoform-specific inhibitor of PIK3 with SF50 more than 1 ?M [1].PI3K (phosphatidylinositol 3-kinase) has 4 catalytic subunits: p110?, ?, ?, ??and ?. |
|||
GSK2636771 |
|||
| B2186-50 | ApexBio | 50 mg | EUR 522 |
|
Description: GSK2636771 is a p110? isoform-specific inhibitor of PIK3 with SF50 more than 1 ?M [1].PI3K (phosphatidylinositol 3-kinase) has 4 catalytic subunits: p110?, ?, ?, ??and ?. |
|||
GSK-2982772 |
|||
| B2232-1 | Biovision | each | EUR 183.6 |
GSK-2982772 |
|||
| B2232-5 | Biovision | each | EUR 548.4 |
GSK-1940029 |
|||
| B2373-25 | Biovision | each | EUR 836.4 |
GSK-1940029 |
|||
| B2373-5 | Biovision | each | EUR 261.6 |
GSK-3039294 |
|||
| B2374-25 | Biovision | each | EUR 810 |
GSK-3039294 |
|||
| B2374-5 | Biovision | each | EUR 248.4 |
GSK-3117391 |
|||
| B2375-25 | Biovision | each | EUR 907.2 |
GSK-3117391 |
|||
| B2375-5 | Biovision | each | EUR 274.8 |
GSK-2814338 |
|||
| B2426-25 | Biovision | each | EUR 810 |
GSK-2814338 |
|||
| B2426-5 | Biovision | each | EUR 248.4 |
GSK-2983559 |
|||
| B2709-1 | Biovision | 1 mg | EUR 150 |
GSK-2983559 |
|||
| B2709-5 | Biovision | 5 mg | EUR 417.6 |
GSK-3368715 |
|||
| B2745-1 | Biovision | 1 mg | EUR 150 |
GSK-3368715 |
|||
| B2745-5 | Biovision | 5 mg | EUR 417.6 |
GSK2292767 |
|||
| B1660-25 | Biovision | each | Ask for price |
GSK2292767 |
|||
| B1660-5 | Biovision | each | Ask for price |
GSK-2879552 |
|||
| B1044-25 | Biovision | each | EUR 1018.8 |
GSK-2110183 |
|||
| B1089-1 | Biovision | each | EUR 222 |
GSK2330672 |
|||
| B1102-1 | Biovision | each | EUR 248.4 |
GSK1325756 |
|||
| B1103-1 | Biovision | each | EUR 222 |
GSK1278863 |
|||
| B1107-1 | Biovision | each | EUR 222 |
GSK1278863 |
|||
| B1107-5 | Biovision | each | EUR 705.6 |
GSK2981278 |
|||
| B1195-25 | Biovision | each | EUR 496.8 |
GSK2981278 |
|||
| B1195-5 | Biovision | each | EUR 210 |
GSK2256098 |
|||
| B1224-25 | Biovision | each | EUR 810 |
GSK2256098 |
|||
| B1224-5 | Biovision | each | EUR 248.4 |
GSK-2334470 |
|||
| B1555-25 | Biovision | each | EUR 907.2 |
GSK-2334470 |
|||
| B1555-5 | Biovision | each | EUR 274.8 |
GSK-1292263 |
|||
| B1556-25 | Biovision | each | EUR 907.2 |
GSK-1292263 |
|||
| B1556-5 | Biovision | each | EUR 274.8 |
GSK-2194069 |
|||
| B1571-25 | Biovision | each | EUR 966 |
GSK-2194069 |
|||
| B1571-5 | Biovision | each | EUR 288 |
GSK2141795 |
|||
| B3590-10 | ApexBio | 10 mg | EUR 351.6 |
GSK2141795 |
|||
| B3590-25 | ApexBio | 25 mg | EUR 686.4 |
GSK2141795 |
|||
| B3590-5 | ApexBio | 5 mg | EUR 216 |
GSK2838232 |
|||
| B5818-10 | ApexBio | 10 mg | EUR 1144.8 |
|
Description: GSK2838232 is an HIV-1 maturation inhibitor [1] [2]. HIV-1 maturation inhibitors disrupt the cleavage of the HIV-1 gag protein immediate precursor by the enzyme HIV-1 protease. |
|||
GSK2838232 |
|||
| B5818-100 | ApexBio | 100 mg | EUR 4620 |
|
Description: GSK2838232 is an HIV-1 maturation inhibitor [1] [2]. HIV-1 maturation inhibitors disrupt the cleavage of the HIV-1 gag protein immediate precursor by the enzyme HIV-1 protease. |
|||
GSK2838232 |
|||
| B5818-5 | ApexBio | 5 mg | EUR 819.6 |
|
Description: GSK2838232 is an HIV-1 maturation inhibitor [1] [2]. HIV-1 maturation inhibitors disrupt the cleavage of the HIV-1 gag protein immediate precursor by the enzyme HIV-1 protease. |
|||
GSK2838232 |
|||
| B5818-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 1024.8 |
|
Description: GSK2838232 is an HIV-1 maturation inhibitor [1] [2]. HIV-1 maturation inhibitors disrupt the cleavage of the HIV-1 gag protein immediate precursor by the enzyme HIV-1 protease. |
|||
GSK2838232 |
|||
| B5818-50 | ApexBio | 50 mg | EUR 3316.8 |
|
Description: GSK2838232 is an HIV-1 maturation inhibitor [1] [2]. HIV-1 maturation inhibitors disrupt the cleavage of the HIV-1 gag protein immediate precursor by the enzyme HIV-1 protease. |
|||
GSK2879552 |
|||
| B5879-25 | ApexBio | 25 mg | EUR 498 |
|
Description: Description:EC50: 38 nM for anti-proliferative growth effect in 19 of 25 AML cell linesLysine specific demethylase 1 (LSD1) is a histone H3K4me1/2 demethylase found in various transcriptional co-repressor complexes. |
|||
GSK2879552 |
|||
| B5879-5 | ApexBio | 5 mg | EUR 192 |
|
Description: Description:EC50: 38 nM for anti-proliferative growth effect in 19 of 25 AML cell linesLysine specific demethylase 1 (LSD1) is a histone H3K4me1/2 demethylase found in various transcriptional co-repressor complexes. |
|||
GSK2879552 |
|||
| B5879-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 212.4 |
|
Description: Description:EC50: 38 nM for anti-proliferative growth effect in 19 of 25 AML cell linesLysine specific demethylase 1 (LSD1) is a histone H3K4me1/2 demethylase found in various transcriptional co-repressor complexes. |
|||
GSK2830371 |
|||
| 2578-1 | Biovision | each | EUR 170.4 |
GSK2830371 |
|||
| 2578-5 | Biovision | each | EUR 496.8 |
GSK1349572 |
|||
| 2288-25 | Biovision | each | EUR 1070.4 |
GSK1349572 |
|||
| 2288-5 | Biovision | each | EUR 314.4 |
GSK-1120212 |
|||
| 1960-1 | Biovision | each | EUR 164.4 |
GSK-1120212 |
|||
| 1960-5 | Biovision | each | EUR 464.4 |
GSK-2126458 |
|||
| 1961-1 | Biovision | each | EUR 189.6 |
GSK-2126458 |
|||
| 1961-5 | Biovision | each | EUR 574.8 |
GSK2636771 |
|||
| 2793-25 | Biovision | each | EUR 705.6 |
GSK2636771 |
|||
| 2793-5 | Biovision | each | EUR 222 |
GSK2269557 |
|||
| C5012-10 | ApexBio | 10 mg | EUR 487.2 |
|
Description: pKi : 9.9 GSK2269557 is an inhibitor of PI3K?. |
|||
GSK2269557 |
|||
| C5012-25 | ApexBio | 25 mg | EUR 996 |
|
Description: pKi : 9.9 GSK2269557 is an inhibitor of PI3K?. |
|||
GSK2269557 |
|||
| C5012-5 | ApexBio | 5 mg | EUR 300 |
|
Description: pKi : 9.9 GSK2269557 is an inhibitor of PI3K?. |
|||
GSK2981278 |
|||
| C3707-10 | ApexBio | 10 mg | EUR 447.6 |
|
Description: GSK2981278 is a ROR?-selective inverse agonist.RAR-related orphan receptor gamma (ROR?) is a protein that in humans is encoded by the RORC gene. The ROR? protein is a DNA-binding transcription factor and is a member of the NR1 subfamily of nuclear receptors. |
|||
GSK2981278 |
|||
| C3707-25 | ApexBio | 25 mg | EUR 908.4 |
|
Description: GSK2981278 is a ROR?-selective inverse agonist.RAR-related orphan receptor gamma (ROR?) is a protein that in humans is encoded by the RORC gene. The ROR? protein is a DNA-binding transcription factor and is a member of the NR1 subfamily of nuclear receptors. |
|||
GSK2981278 |
|||
| C3707-5 | ApexBio | 5 mg | EUR 278.4 |
|
Description: GSK2981278 is a ROR?-selective inverse agonist.RAR-related orphan receptor gamma (ROR?) is a protein that in humans is encoded by the RORC gene. The ROR? protein is a DNA-binding transcription factor and is a member of the NR1 subfamily of nuclear receptors. |
|||
GSK2881078 |
|||
| C4768-10 | ApexBio | 10 mg | EUR 447.6 |
|
Description: GSK2881078 is a potent and selective androgen receptor modulator (SARM) [1]. Steroidal nuclear receptor (NR) ligands play important roles in the health of both men and women. |
|||
GSK2881078 |
|||
| C4768-25 | ApexBio | 25 mg | EUR 908.4 |
|
Description: GSK2881078 is a potent and selective androgen receptor modulator (SARM) [1]. Steroidal nuclear receptor (NR) ligands play important roles in the health of both men and women. |
|||
GSK2881078 |
|||
| C4768-5 | ApexBio | 5 mg | EUR 278.4 |
|
Description: GSK2881078 is a potent and selective androgen receptor modulator (SARM) [1]. Steroidal nuclear receptor (NR) ligands play important roles in the health of both men and women. |
|||
GSK2194069 |
|||
| B8005-5 | ApexBio | 5 mg | EUR 289.2 |
|
Description: IC50: 7.7 nMGSK 2194069 is a potent human fatty acid synthase inhibitor. Human fatty acid synthase (hFAS) is a multifunctional enzyme solely responsible for the de novo synthesis of long chain fatty acids. |
|||
GSK2606414 |
|||
| A3448-10 | ApexBio | 10 mg | EUR 240 |
|
Description: GSK2606414 is a selective inhibitor of PERK with IC50 value of 0.4nM.[1]PERK (PRKR-like endoplasmic reticulum kinase or protein kinase R (PKR)-like endoplasmic reticulum kinase) is also known as EIF2AK3 (Eukaryotic translation initiation factor 2-alpha kinase 3). |
|||
GSK2606414 |
|||
| A3448-200 | ApexBio | 200 mg | EUR 1312.8 |
|
Description: GSK2606414 is a selective inhibitor of PERK with IC50 value of 0.4nM.[1]PERK (PRKR-like endoplasmic reticulum kinase or protein kinase R (PKR)-like endoplasmic reticulum kinase) is also known as EIF2AK3 (Eukaryotic translation initiation factor 2-alpha kinase 3). |
|||
GSK2606414 |
|||
| A3448-5 | ApexBio | 5 mg | EUR 196.8 |
|
Description: GSK2606414 is a selective inhibitor of PERK with IC50 value of 0.4nM.[1]PERK (PRKR-like endoplasmic reticulum kinase or protein kinase R (PKR)-like endoplasmic reticulum kinase) is also known as EIF2AK3 (Eukaryotic translation initiation factor 2-alpha kinase 3). |
|||
GSK2606414 |
|||
| A3448-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 205.2 |
|
Description: GSK2606414 is a selective inhibitor of PERK with IC50 value of 0.4nM.[1]PERK (PRKR-like endoplasmic reticulum kinase or protein kinase R (PKR)-like endoplasmic reticulum kinase) is also known as EIF2AK3 (Eukaryotic translation initiation factor 2-alpha kinase 3). |
|||
GSK2606414 |
|||
| A3448-50 | ApexBio | 50 mg | EUR 547.2 |
|
Description: GSK2606414 is a selective inhibitor of PERK with IC50 value of 0.4nM.[1]PERK (PRKR-like endoplasmic reticulum kinase or protein kinase R (PKR)-like endoplasmic reticulum kinase) is also known as EIF2AK3 (Eukaryotic translation initiation factor 2-alpha kinase 3). |
|||
S/GSK1349572 |
|||
| A4074-10 | ApexBio | 10 mg | EUR 379.2 |
|
Description: S/GSK1349572, also known as dolutegravir, is a novel and potent inhibitor of human immunodeficiency virus (HIV) integrase (IN) blocking the strand transfer of integration of the viral genome into the host cell?s DNA. |
|||
S/GSK1349572 |
|||
| A4074-100 | ApexBio | 100 mg | EUR 1562.4 |
|
Description: S/GSK1349572, also known as dolutegravir, is a novel and potent inhibitor of human immunodeficiency virus (HIV) integrase (IN) blocking the strand transfer of integration of the viral genome into the host cell?s DNA. |
|||
S/GSK1349572 |
|||
| A4074-5 | ApexBio | 5 mg | EUR 296.4 |
|
Description: S/GSK1349572, also known as dolutegravir, is a novel and potent inhibitor of human immunodeficiency virus (HIV) integrase (IN) blocking the strand transfer of integration of the viral genome into the host cell?s DNA. |
|||
S/GSK1349572 |
|||
| A4074-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 313.2 |
|
Description: S/GSK1349572, also known as dolutegravir, is a novel and potent inhibitor of human immunodeficiency virus (HIV) integrase (IN) blocking the strand transfer of integration of the viral genome into the host cell?s DNA. |
|||
S/GSK1349572 |
|||
| A4074-50 | ApexBio | 50 mg | EUR 880.8 |
|
Description: S/GSK1349572, also known as dolutegravir, is a novel and potent inhibitor of human immunodeficiency virus (HIV) integrase (IN) blocking the strand transfer of integration of the viral genome into the host cell?s DNA. |
|||
GSK1070916 |
|||
| A4127-10 | ApexBio | 10 mg | EUR 268.8 |
|
Description: GSK1070916 is a potent and selective inhibitor of Aurora B/C Kinase with Ki values of 0.38nM and 1.5nM, respectively [1]. |
|||
GSK1070916 |
|||
| A4127-200 | ApexBio | 200 mg | EUR 1730.4 |
|
Description: GSK1070916 is a potent and selective inhibitor of Aurora B/C Kinase with Ki values of 0.38nM and 1.5nM, respectively [1]. |
|||
GSK1070916 |
|||
| A4127-5 | ApexBio | 5 mg | EUR 184.8 |
|
Description: GSK1070916 is a potent and selective inhibitor of Aurora B/C Kinase with Ki values of 0.38nM and 1.5nM, respectively [1]. |
|||
GSK1070916 |
|||
| A4127-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 268.8 |
|
Description: GSK1070916 is a potent and selective inhibitor of Aurora B/C Kinase with Ki values of 0.38nM and 1.5nM, respectively [1]. |
|||
GSK1070916 |
|||
| A4127-50 | ApexBio | 50 mg | EUR 616.8 |
|
Description: GSK1070916 is a potent and selective inhibitor of Aurora B/C Kinase with Ki values of 0.38nM and 1.5nM, respectively [1]. |
|||
GSK2292767 |
|||
| B6173-10 | ApexBio | 10 mg | EUR 556.8 |
|
Description: pKi: 10.1GSK2292767 is a potent and selective PI3K? inhibitor. |
|||
GSK2292767 |
|||
| B6173-25 | ApexBio | 25 mg | EUR 1155.6 |
|
Description: pKi: 10.1GSK2292767 is a potent and selective PI3K? inhibitor. |
|||
GSK2292767 |
|||
| B6173-5 | ApexBio | 5 mg | EUR 336 |
|
Description: pKi: 10.1GSK2292767 is a potent and selective PI3K? inhibitor. |
|||
GSK2190915 |
|||
| B1891-1 | Biovision | each | EUR 183.6 |
GSK2190915 |
|||
| B1891-5 | Biovision | each | EUR 535.2 |
GSK-1059615 |
|||
| 9450-25 | Biovision | each | EUR 652.8 |
GSK-1059615 |
|||
| 9450-5 | Biovision | each | EUR 210 |
GSK-2656157 |
|||
| 9466-25 | Biovision | each | EUR 705.6 |
GSK-2656157 |
|||
| 9466-5 | Biovision | each | EUR 222 |
GSK-2606414 |
|||
| 9467-25 | Biovision | each | EUR 757.2 |
GSK-2606414 |
|||
| 9467-5 | Biovision | each | EUR 235.2 |
GSK2126458 |
|||
| A8556-10 | ApexBio | 10 mg | EUR 268.8 |
|
Description: GSK2126458 is an inhibitor of PI3K/mTOR with Ki value of 19 pM for PI3K [1]. |
|||
GSK2126458 |
|||
| A8556-5 | ApexBio | 5 mg | EUR 226.8 |
|
Description: GSK2126458 is an inhibitor of PI3K/mTOR with Ki value of 19 pM for PI3K [1]. |
|||
GSK2126458 |
|||
| A8556-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 240 |
|
Description: GSK2126458 is an inhibitor of PI3K/mTOR with Ki value of 19 pM for PI3K [1]. |
|||
GSK2126458 |
|||
| A8556-50 | ApexBio | 50 mg | EUR 644.4 |
|
Description: GSK2126458 is an inhibitor of PI3K/mTOR with Ki value of 19 pM for PI3K [1]. |
|||
GSK1292263 |
|||
| A8439-10 | ApexBio | 10 mg | EUR 254.4 |
|
Description: GSK1292263 is a novel agonist of GPR119 receptor agonist and is used for the treatment of type 2 diabetes. GPR119 is described as a class A (rhodopsin-type) orphan GPCR with no close primary sequence relative in the human genome. |
|||
GSK1292263 |
|||
| A8439-200 | ApexBio | 200 mg | EUR 2022 |
|
Description: GSK1292263 is a novel agonist of GPR119 receptor agonist and is used for the treatment of type 2 diabetes. GPR119 is described as a class A (rhodopsin-type) orphan GPCR with no close primary sequence relative in the human genome. |
|||
GSK1292263 |
|||
| A8439-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 379.2 |
|
Description: GSK1292263 is a novel agonist of GPR119 receptor agonist and is used for the treatment of type 2 diabetes. GPR119 is described as a class A (rhodopsin-type) orphan GPCR with no close primary sequence relative in the human genome. |
|||
GSK1292263 |
|||
| A8439-50 | ApexBio | 50 mg | EUR 714 |
|
Description: GSK1292263 is a novel agonist of GPR119 receptor agonist and is used for the treatment of type 2 diabetes. GPR119 is described as a class A (rhodopsin-type) orphan GPCR with no close primary sequence relative in the human genome. |
|||
GSK1059615 |
|||
| E1KS1360 | EnoGene | 10mg | EUR 1849.2 |
GSK1292263 |
|||
| E1KS2149 | EnoGene | 10mg | EUR 1849.2 |
GSK2850163 |
|||
| HY-U00459 | MedChemExpress | 10mM/1mL | EUR 181.2 |
GSK3179106 |
|||
| HY-100459 | MedChemExpress | 1mg | EUR 308.4 |
GSK2256098 |
|||
| HY-100498 | MedChemExpress | 200mg | EUR 2952 |
GSK2193874 |
|||
| HY-100720 | MedChemExpress | 100mg | EUR 1200 |
GSK1059865 |
|||
| HY-101534 | MedChemExpress | 100mg | EUR 2869.2 |
GSK3326595 |
|||
| HY-101563 | MedChemExpress | 100mg | EUR 680.4 |
GSK2982772 |
|||
| HY-101760 | MedChemExpress | 10mM/1mL | EUR 265.2 |
GSK3145095 |
|||
| HY-111946 | MedChemExpress | 10mM/1mL | EUR 482.4 |
The antidepressant-like actions of NAc DBS and sham electrode placements have been related to a rise in ranges of IL and vHIP phospho-GSK3β and phospho-mTOR, nonetheless, no variations in these protein ranges have been noticed within the dHIP area.
These knowledge recommend that early response to electrode placement within the NAc, no matter whether or not energetic DBS or sham, has antidepressant-like results within the ACTH-model of antidepressant resistance related to distal upregulation of phospho-GSK3β and phospho-mTOR within the IL and vHIP areas of the temper community.
